Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Updated appropriate use criteria for amyloid and tau PET : A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup

Rabinovici, Gil D. ; Knopman, David S. ; Arbizu, Javier ; Benzinger, Tammie L.S. ; Donohoe, Kevin J. ; Hansson, Oskar LU orcid ; Herscovitch, Peter ; Kuo, Phillip H. ; Lingler, Jennifer H. and Minoshima, Satoshi , et al. (2025) In Alzheimer's and Dementia 21(1).
Abstract

INTRODUCTION: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. RESULTS: For amyloid PET,... (More)

INTRODUCTION: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. RESULTS: For amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. Highlights: A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Alzheimer's disease, amyloid PET, appropriate use criteria, biomarkers, brain pathology, clinical care, cognitive impairment, dementia, diagnosis, early detection, memory disorders, molecular imaging, neuroimaging, neurology, PET imaging, positron emission tomography, tau PET, therapeutic strategies, treatment
in
Alzheimer's and Dementia
volume
21
issue
1
article number
e14338
publisher
Wiley
external identifiers
  • pmid:39778970
  • scopus:85214258428
ISSN
1552-5260
DOI
10.1002/alz.14338
language
English
LU publication?
yes
additional info
Publisher Copyright: © 2025 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
id
372134cc-2a79-45df-9c4c-0e3a447278f0
date added to LUP
2025-03-25 13:09:20
date last changed
2025-03-25 13:10:28
@article{372134cc-2a79-45df-9c4c-0e3a447278f0,
  abstract     = {{<p>INTRODUCTION: The Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging convened a multidisciplinary workgroup to update appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. METHODS: The workgroup identified key research questions that guided a systematic literature review on clinical amyloid/tau PET. Building on this review, the workgroup developed 17 clinical scenarios in which amyloid or tau PET may be considered. A modified Delphi approach was used to rate each scenario by consensus as “rarely appropriate,” “uncertain,” or “appropriate.” Ratings were performed separately for amyloid and tau PET as stand-alone modalities. RESULTS: For amyloid PET, seven scenarios were rated as appropriate, two as uncertain, and eight as rarely appropriate. For tau PET, five scenarios were rated as appropriate, six as uncertain, and six as rarely appropriate. DISCUSSION: AUC for amyloid and tau PET provide expert recommendations for clinical use of these technologies in the evolving landscape of diagnostics and therapeutics for Alzheimer's disease. Highlights: A multidisciplinary workgroup convened by the Alzheimer's Association and the Society of Nuclear Medicine and Molecular Imaging updated the appropriate use criteria (AUC) for amyloid positron emission tomography (PET) and to develop AUC for tau PET. The goal of these updated AUC is to assist clinicians in identifying clinical scenarios in which amyloid or tau PET may be useful for guiding the diagnosis and management of patients who have, or are at risk for, cognitive decline These updated AUC are intended for dementia specialists who spend a significant proportion of their clinical effort caring for patients with cognitive complaints, as well as serve as a general reference for a broader audience interested in implementation of amyloid and tau PET in clinical practice.</p>}},
  author       = {{Rabinovici, Gil D. and Knopman, David S. and Arbizu, Javier and Benzinger, Tammie L.S. and Donohoe, Kevin J. and Hansson, Oskar and Herscovitch, Peter and Kuo, Phillip H. and Lingler, Jennifer H. and Minoshima, Satoshi and Murray, Melissa E. and Price, Julie C. and Salloway, Stephen P. and Weber, Christopher J. and Carrillo, Maria C. and Johnson, Keith A.}},
  issn         = {{1552-5260}},
  keywords     = {{Alzheimer's disease; amyloid PET; appropriate use criteria; biomarkers; brain pathology; clinical care; cognitive impairment; dementia; diagnosis; early detection; memory disorders; molecular imaging; neuroimaging; neurology; PET imaging; positron emission tomography; tau PET; therapeutic strategies; treatment}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Wiley}},
  series       = {{Alzheimer's and Dementia}},
  title        = {{Updated appropriate use criteria for amyloid and tau PET : A report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup}},
  url          = {{http://dx.doi.org/10.1002/alz.14338}},
  doi          = {{10.1002/alz.14338}},
  volume       = {{21}},
  year         = {{2025}},
}